Aug 12, 2020
PDL BioPharma Enters Into Settlement Agreement with Wellstat
May 21, 2020
PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders
May 18, 2020
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
May 07, 2020
PDL BioPharma Reports 2020 First Quarter Financial Results
May 05, 2020
PDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders
Apr 30, 2020
PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020
Mar 11, 2020
PDL BioPharma Reports 2019 Fourth Quarter and Full Year Financial Results and Announces Plan to Dissolve the Company by Year-End 2020
Mar 04, 2020
PDL BioPharma to Announce 2019 Fourth Quarter and Full Year Financial Results on March 11, 2020
Feb 28, 2020
PDL BioPharma Enters into Cooperation Agreement with Engine Capital
Feb 25, 2020
PDL BioPharma to Participate in the Cowen and Company 40th Annual Health Care Conference
Dec 19, 2019
PDL BioPharma Announces Upcoming Changes to its Board of Directors
Dec 16, 2019
PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million
Dec 13, 2019
PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024
Dec 03, 2019
PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
Nov 14, 2019
PDL BioPharma Reaffirms Commitment To Shareholder Value Creation
Nov 06, 2019
PDL BioPharma Reports 2019 Third Quarter Financial Results
Oct 30, 2019
PDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019
Oct 24, 2019
PDL BioPharma Responds to Letter from Engine Capital
Sep 26, 2019
PDL BioPharma to Participate in the 2019 Cantor Fitzgerald Global Healthcare Conference
Aug 07, 2019
PDL BioPharma Reports 2019 Second Quarter Financial Results